Bibliography
- Fong TM. Advances in anti-obesity therapeutics. Expert Opin Investig Drugs 2005;14:243-50
- Zhao H, Liu G. Growth hormone secretagogue receptor antagonists as anti-obesity therapies? Still an open question. Curr Opin Drug Discov Dev 2006;9:509-15
- Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999;402:656-60
- Peino R, Baldelli R, Rodriguez-Garcia J, et al. Ghrelin -induced growth hormone secretion in humans. Eur J Endocrinol 2000;143:R11-4
- Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature 2000;407:908-13
- Wren AM, Small CJ, Ward HL, et al. The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology 2000;141:4325-8
- Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 2001;86:5992-5
- Sun Y, Wang P, Zheng H, et al. Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor. Proc Natl Acad Sci USA 2004;101:4679-84
- Zigman JM, Nakano Y, Coppari R, et al. Mice lacking ghrelin receptors resist the development of diet-induced obesity. J Clin Invest 2005;115:3564-72
- ShutoY, Shibasaki T, Otagiri A, et al. Hypothalamic growth hormone secretagogue receptor regulates growth hormone secretion, feeding, and adiposity. J Clin Invest 2002;109:1429-36
- Sun Y, Ahmed S, Smith RG. Deletion of ghrelin impairs neither growth nor appetite. Mol Cell Biol 2003;23:7973-81
- Wortley KE, Anderson KD, Garcia K, et al. Genetic deletion of ghrelin does not decrease food intake but influences metabolic fuel preference. Proc Natl Acad Sci USA 2004;101:4679-84
- Wortley KE, del Rincon JP, Murray JD, et al. Absence of ghrelin protects against early-onset obesity. J Clin Invest 2005;115:3573-8
- De Smet B, Depoortere I, Moechars D, et al. Energy homeostasis and gastric emptying in ghrelin knockout mice. J Pharm Exp Ther 2006;316:431-9
- Nakazato M, Murakami N, Date Y, et al. A role for ghrelin in the central regulation of feeding. Nature 2001;409:194-8
- Asakawa A, Inui A, Kaga T, et al. Antagonism of ghrelin receptor reduces food intake and body weight gain in mice. Gut 2003;52:947-52
- Shearman LP, Wang SP, Helmling S, et al. Ghrelin neutralization by a ribonucleic acid-SPM ameliorates obesity in diet-induced obese mice. Endocrinology 2006;147:1517-26
- Cummings DE, Frayo RS, Marmonier C, et al. Plasma ghrelin levels and hunger scores in humans initiating meals voluntarily without time- and food-related cues. Am J Physiol Endocrinol Metab 2004;287:E297-304
- Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002;346:1623-30
- Paul DR, Kramer M, Rhodes DG, et al. Preprandial ghrelin is not affected by macronutrient intake, energy intake or energy expenditure. J Negative Results Biomed 2005;4:2
- Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 2001;86:5992-5
- Tassone F, Broglio F, Destefanis S, et al. Neuroendocrine and metabolic effects of acute ghrelin administration in human obesity. J Clin Endocrinol Metab 2003;88:5478-83
- Schmid DA, Held K, Ising M, et al. Ghrelin stimulates appetite, imagination of food, GH, ACTH, and cortisol, but does not affect leptin in normal controls. Neuropsychopharmacology 2005;30:1187-92
- Salbe AD, Tschöp MH, DelParigi A, et al. Negative relationship between fasting plasma ghrelin concentrations and ad libitum food intake. J Clin Endocrin Metab 2004;89:2951-6
- Colca JR. Discontinued drugs in 2006: renal, endocrine and metabolic drugs. Expert Opin Investig Drugs 2007;16:1517-23
- Abbott Laboratories. Preparation of diaminopyrimidines as growth hormone secretagogue receptor (GHS-R) antagonists. US20050171131; 2005
- Liu B, Liu M, Xin Z, et al. Optimization of 2,4-diaminopyrimidines as GHS-R antagonists: side chain exploration. Bioorg Med Chem Lett 2006;16:1864-8
- Serby MD, Zhao H, Szczepankiewicz BG, et al. 2,4-Diaminopyrimidine derivatives as potent growth hormone secretagogue receptor antagonists. J Med Chem 2006;49:2568-78
- Xin Z, Serby MD, Zhao H, et al. Discovery and pharmacological evaluation of growth hormone secretagogue receptor antagonists. J Med Chem 2006;49:4459-69
- Weir EC, Cashmore AR, Dreyer RN, et al. Pharmacology and toxicity of a potent “nonclassical” 2,4-diamino quinazoline folate antagonist, trimetrexate, in normal dogs. Cancer Res 1982;42:1696-702
- Bayer Pharm. Corp. Preparation of quinazolinone derivatives useful for the regulation of glucose homeostasis and food intake. WO2006012577; 2006
- Rudolph J, Esler WP, O'Connor S, et al. Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity. J Med Chem 2007;50:5202-16
- Esler WP, Rudolph J, Claus TH, et al. Small-molecule ghrelin receptor antagonists improve glucose tolerance, suppress appetite, and promote weight loss. Endocrinology 2007;148:5175-85
- Elixir Pharma., Inc. Therapeutic compounds and uses thereof. WO2005046682; 2005
- Merck & Co. Preparation of substituted pyrazoles as ghrelin receptor antagonists. WO2008008286; 2008
- Tranzyme Pharma., Inc. Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same. WO2006137974; 2006
- Tranzyme Pharma., Inc. Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same. WO2006046977; 2006
- Zentaris GmbH/Le Centre National De La Recherche Scientifique. Preparation of tryptophan-derived triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors. US2007037857; 2007
- Zentaris GmbH/Le Centre National De La Recherche Scientifique. Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors. EP1757290; 2007
- Zentaris GmbH/Le Centre National De La Recherche Scientifique. Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors. WO2007020013; 2007
- Demange L, Boeglin D, Moulin A, et al. Synthesis and pharmacological in vitro and in vivo evaluations of novel triazole derivatives as ligands of the ghrelin receptor. 1. J Med Chem 2007;50:1939-57
- Moulin A, Demange L, Berge G, et al. Toward potent ghrelin receptor ligands based on trisubstituted 1,2,4-triazole structure. 2. Synthesis and pharmacological in vitro and in vivo evaluations. J Med Chem 2007;50:5790-806
- Moulin A, Demange L, Ryan J, et al. New trisubstituted 1,2,4-triazole derivatives as potent ghrelin receptor antagonists. 3. Synthesis and pharmacological in vitro and in vivo evaluations. J Med Chem 2008;51:689-93
- Scheen AJ. The future of obesity: new drugs versus lifestyle interventions. Expert Opin Investig Drugs 2008;17:263-4
- Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007;369:71-7
- Halem HA, Taylor JE, Dong JZ, et al. A novel growth hormone secretagogue-1a receptor antagonist that blocks ghrelin-induced growth hormone secretion but induces increased body weight gain. Neuroendocrinology 2005;81:339-49
- Zhang JV, Ren PG, Avsian-Kretchmer O, et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science 2005;310:996-9
- Gourcerol G, St-Pierre DH, Taché Y. Lack of obestatin effects on food intake: should obestatin be renamed ghrelin-associated peptide (GAP)? Regul Pept 2007;141:1-7
- Asakawa A, Inui A, Fujimiya M, et al. Stomach regulates energy balance via acylated ghrelin and desacyl ghrelin. Gut 2005;54:18-24
- Chen CY, Chao Y, Chang FY, et al. Intracisternal des-acyl ghrelin inhibits food intake and non-nutrient gastric emptying in conscious rats. Int J Mol Med 2005;16:695-9
- Toshinai K, Yamaguchi H, Sun Y, et al. Des-acyl ghrelin induces food intake by a mechanism independent of the growth hormone secretagogue receptor. Endocrinology 2006;147:2306-14
- Liu J, Prudom CE, Nass R, et al. Novel ghrelin assays provide evidence for independent regulation of ghrelin acylation and secretion in healthy young men. J Clin Endocrinol Metab 2008;93:1980-7
- Halaas J, Gajiwala K, Maffei M, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995;269:543-6
- Pelleymounter M, Cullen M, Baker M, et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995;269:540-3
- Campfield LA, Smith FJ, Guisez J, et al. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science 1995;269:546-9
- Halaas JL, Boozer C, Blair-West J, et al. Physiological response to long-term peripheral and central leptin infusion in lean and obese mice. Proc Natl Acad Sci USA 1997;94:8878-83
- Amylin Pharmaceuticals, Inc. Press Release 15 November 2007. Amylin Pharmaceuticals has recently reported on its website that combination of pramlintide (an analogue of human amylin) and recombinant human leptin reduced body weight significantly more than treatment with pramlintide alone. Available from: http://investors.amylin.com/phoenix.zhtml?c=101911&p=irol-newsArticle_print&ID=1078402&highlight=
- Fong TM. Development of anti-obesity agents: drugs that target neuropeptide and neurotransmitter systems. Expert Opin Investig Drugs 2008;17:321-5
- Ghigo E, Broglio F, Arvat E, et al. Ghrelin: more than a natural GH secretagogue and/or an orexigenic factor. Clin Endocrinol 2005;62:1-17
- Holst B, Cygankiewicz A, Jensen TH, et al. High constitutive signaling of the ghrelin receptor-identification of a potent inverse agonist. Mol Endocrinol 2003;17:2201-10
- 7TM Pharma A/S. Ghrelin receptor inverse agonists for regulation of feeding behaviors. WO2004056869; 2004